There is no blood test available for Parkinson’s disease right now. Diagnosis still relies on a neurologist’s clinical evaluation of symptoms like tremor, stiffness, and slowness of movement. However, new laboratory tests that detect the hallmark protein behind Parkinson’s are now commercially available using spinal fluid and skin biopsies, and researchers are working to adapt the technology to a simple blood draw.
How Parkinson’s Is Currently Diagnosed
Parkinson’s is one of the few major diseases still diagnosed primarily by observation. A neurologist watches how you move, tests your reflexes, asks about your symptoms, and applies standardized clinical criteria. The International Parkinson and Movement Disorder Society, which sets the formal diagnostic guidelines, does not include any blood test in its criteria. The only lab-based finding it recognizes as a supporting clue is a specialized heart imaging scan that measures nerve function.
In uncertain cases, doctors sometimes order a DaTscan, a type of brain imaging that shows whether dopamine-producing nerve cells are functioning normally. This can help distinguish Parkinson’s from conditions that mimic it, but it can’t confirm a Parkinson’s diagnosis on its own. It also can’t differentiate Parkinson’s from other, rarer neurodegenerative diseases that affect the same brain cells.
The Alpha-Synuclein Test: Close, but Not in Blood Yet
The biggest breakthrough in Parkinson’s testing centers on a protein called alpha-synuclein. In people with Parkinson’s, this protein misfolds and clumps together inside nerve cells, eventually killing them. A test called the alpha-synuclein seed amplification assay (SAA) can detect these abnormal protein clumps in spinal fluid with about 93 percent accuracy, according to data from the Michael J. Fox Foundation’s landmark Parkinson’s research program.
In one large research cohort, the assay correctly identified 95 percent of people who had Parkinson’s and correctly ruled it out in 95 percent of healthy controls. Those numbers make it one of the most promising diagnostic tools for the disease to date.
The catch: this test requires a spinal tap, a procedure where a needle is inserted into the lower back to collect cerebrospinal fluid. A commercially available version of this test, called SAAmplify, can now be ordered by a physician and costs $1,500 out of pocket. Insurance does not currently cover it, though the manufacturer offers financial assistance and is pursuing coverage from Medicare, Medicaid, and private insurers.
Researchers hope the same technology can eventually work with a blood sample instead of spinal fluid, which would make testing far simpler and more accessible. That transition hasn’t happened yet. As Mayo Clinic notes, the assay is still primarily a research tool, and adapting it for blood is an active area of development.
A Skin Biopsy Option Exists Now
While a blood test remains unavailable, there is another option that doesn’t require a spinal tap. The Syn-One test uses a small skin biopsy, typically taken from the neck or leg, to look for abnormal alpha-synuclein deposits in the tiny nerve fibers of the skin. Research suggests that these protein deposits in skin tissue can help confirm or rule out Parkinson’s with meaningful accuracy, particularly in cases where clinical diagnosis is uncertain.
This test is currently available through Medicare and some private insurers, making it more accessible than the spinal fluid assay for many patients. Your neurologist would need to order it and send the tissue sample to the testing company’s lab.
Other Blood Markers Under Investigation
Alpha-synuclein isn’t the only molecule researchers are tracking in blood. Neurofilament light chain (NfL) is a protein released when nerve cells are damaged. Blood levels of NfL rise in several neurodegenerative diseases, and the technology to measure it from a standard blood draw already exists.
NfL isn’t specific enough to diagnose Parkinson’s on its own. Its levels tend to be relatively normal in typical Parkinson’s but spike significantly in related conditions like progressive supranuclear palsy and multiple system atrophy, which involve more widespread nerve damage. This makes NfL potentially useful as a sorting tool: if someone has parkinsonian symptoms and very high NfL levels, it raises suspicion that something other than typical Parkinson’s may be responsible. Because NfL in blood closely mirrors NfL in spinal fluid, it could eventually be combined with other blood markers to build a more complete diagnostic picture without invasive procedures.
Why a Blood Test Matters So Much
Parkinson’s can take years to diagnose. Early symptoms like a slight tremor in one hand, subtle changes in handwriting, or a quieter voice are easy to dismiss or attribute to aging. Studies estimate that by the time most people receive a clinical diagnosis, they’ve already lost a substantial portion of their dopamine-producing brain cells. An accurate blood test would allow detection much earlier, potentially before motor symptoms even appear.
Early detection also matters for clinical trials. Many experimental treatments aim to slow or stop the disease’s progression, but they’re most likely to work if given before extensive brain damage has occurred. Right now, recruiting the right patients for these trials is difficult without an objective biological test. A blood-based assay would transform both everyday diagnosis and the pace of research.
For now, if you’re experiencing symptoms that concern you, the path to diagnosis runs through a neurologist’s clinical evaluation. If your case is uncertain, your doctor may consider the spinal fluid assay or skin biopsy as supporting evidence. A true blood test for Parkinson’s is not yet part of clinical practice, but the science behind it is advancing quickly enough that it may become available within the next several years.